Hims & Hers Health shares gain almost 4% after FTC files complaint and legal actions mount

Traders Union
All News
Stocks
Hims & Hers Health rises 3.86% today

Highlights

The FTC filed a complaint against Hims & Hers Health for alleged business misconduct, triggering class action lawsuits by several law firms on behalf of investors with losses.
Hims & Hers Health acquired Eucalyptus for approximately $225 million and posted a net loss of $142 million over the trailing four quarters ending June 30, 2026.
Shares of Hims & Hers Health trade below short-term moving averages with mixed momentum, and are likely to move within a $27.46 to $30.98 range in the next five days, with a higher probability of a downward move.

Investor lawsuits escalate following FTC complaint and recent acquisition

The U.S. Federal Trade Commission filed a complaint against Hims & Hers Health on July 29, 2026, alleging serious business misconduct. Multiple law firms, including Bronstein, Gewirtz & Grossman LLC and Hagens Berman, subsequently announced class action lawsuits on behalf of investors who experienced substantial losses. Earlier in June, the company completed the acquisition of Eucalyptus, expanding its international presence and making an upfront payment of approximately $225 million, although it reported a net loss of $142 million over the four quarters ending June 30, 2026.

Anton Kharitonov, expert at Traders Union, views the recent rally in Hims & Hers Health as fragile given the ongoing regulatory headwinds. He observes that the stock remains technically weak, with both MACD and RSI signaling sustained selling pressure. Kharitonov points out the gravity of the FTC complaint and subsequent class actions, underlining elevated legal and reputational risks. The weak trend in ADX and negative oscillators highlight a lack of conviction among buyers. He remains skeptical about short-term upside, stating, "Any move above $29.23 appears unsustainable while legal uncertainties and persistent technical weakness dominate the landscape."

Viktoras Karapetjanc, expert at Traders Union, notes that despite headline concerns, Hims & Hers Health is showing resilience above its 200-day moving average. He sees strong acquisition activity and international growth as reinforcing the company's bullish structure. Karapetjanc emphasizes that the current consolidation sets up multiple opportunities for investors looking for further growth. The expert remains confident in the longer-term outlook, saying, "I expect further advances as the company digests recent expansion — the market offers several promising setups for committed bulls."

Parshwa Turakhiya, analyst, highlights a battle between persistent selling pressure and intraday strength in Hims & Hers Health. He observes that oversold signals from both the Stochastic RSI and CCI could attract short-term traders, despite the caution implied by the MACD and low ADX. Turakhiya believes that sentiment remains sensitive to regulatory news, driving high volatility in the near term. "Sideways action around $29.00 creates potential for sharp moves — nimble traders should be ready to act if either support or resistance breaks," he says.

Bearish momentum persists despite support holding above long-term average

Hims & Hers Health is currently trading just below both the 20-day and 50-day moving averages, which are $29.23 and $29.25, while remaining above the 200-day moving average at $27.25. This positioning suggests the stock faces short- and medium-term pressure from sellers, though the long-term trend remains bullish with the 50-day average aligned positively over the 200-day. The near-term ceiling stands at $29.23, while immediate support is seen at $29.06, marked by the Ichimoku Kijun. Momentum signals present a mixed picture: the Moving Average Convergence Divergence (MACD) and Relative Strength Index (RSI) both point to selling pressure, with the RSI at 46.18 reflecting muted momentum and the MACD confirming a bearish tilt. The Average Directional Index (ADX) at 13.6 indicates a weak trend overall. Oversold readings from the Stochastic RSI and Commodity Channel Index (CCI) are prominent, and the Bull/Bear Power (BBP) is slightly positive at 0.02, showing buyers narrowly dominate intraday momentum, but the oversold forecast underscores ongoing weakness. The Awesome Oscillator (AO) also reinforces the sell bias. The stock is up $1.09, or 3.86%, on an upside gap of about $0.41 (1.46%), trading near the high of today’s range with intraday volatility at 4.90%. The overall intraday tone is one of persistent strength toward session highs, yet momentum and oscillators signal caution.

Previously it was reported that Hims & Hers Health expanded its international footprint by launching digital healthcare services in new European markets. The current backdrop introduces heightened legal and regulatory risk, making sustained price action above the $29.23 ceiling a critical threshold to watch for signs of bullish reversal in the coming sessions.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.